- Home
- OGN
OGN
Organon & Co.
as 06-20-2025 4:00pm EST
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
| Founded: | 1923 | Country: | United States |
| Employees: | N/A | City: | JERSEY CITY |
| Market Cap: | 2.5B | IPO Year: | N/A |
| Target Price: | $18.00 | AVG Volume (30 days): | 4.6M |
| Analyst Decision: | Hold | Number of Analysts: | 4 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 2.88 | EPS Growth: | -29.44 |
| 52 Week Low/High: | $8.01 - $23.10 | Next Earning Date: | 08-05-2025 |
| Revenue: | $6,294,000,000 | Revenue Growth: | -0.83% |
| Revenue Growth (this year): | -1.84% | Revenue Growth (next year): | 1.11% |
Stock Insider Trading Activity of Organon & Co. (OGN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| COX CARRIE SMITH | OGN | Director | May 14 '25 | Buy | $8.07 | 12,469 | $100,591.16 | 12,469 | |
| Weaver Kirke | OGN | Gen. Counsel & Corp. Secy. | May 6 '25 | Buy | $9.21 | 8,045 | $74,054.23 | 52,489 | |
| WALSH MATTHEW M | OGN | Chief Financial Officer | May 5 '25 | Buy | $8.82 | 11,400 | $100,548.00 | 144,484 |
Latest Organon & Co. News
OGN Breaking Stock News: Dive into OGN Ticker-Specific Updates for Smart Investing
Zacks
4 days ago
All You Need to Know About Organon (OGN) Rating Upgrade to Buy
Zacks
4 days ago
OGN or DOCS: Which Is the Better Value Stock Right Now?
Argus Research
10 days ago
OGN: Raising target price to $11.00
Business Wire
25 days ago
US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon HADLIMA™ (adalimumab-bwwd) Injection
Argus Research
a month ago
OGN: Rating decreased to a HOLD
Simply Wall St.
a month ago
CEO & Director of Organon Picks Up 14% More Stock
Simply Wall St.
a month ago
Organon (NYSE:OGN) Reports Decreased Earnings Affecting Investor Sentiment
Simply Wall St.
a month ago
Organon & Co. (NYSE:OGN) Goes Ex-Dividend Soon
Compare OGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OGN Organon & Co. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.